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Abstract. We present a large case-control candidate gene study of leprosy susceptibility. Thirty-eight polymorphic
sites from 13 genes were investigated for their role in susceptibility to leprosy by comparing 270 cases with 452 controls
in Karonga district, northern Malawi. Homozygotes for a silent T→C change in codon 352 of the vitamin D receptor gene
appeared to be at high risk (odds ratio [OR]  4.3, 95% confidence interval [CI]  1.6−11.4, P = 0.004), while
homozygotes for the McCoy b blood group defining variant K1590E in exon 29 of the complement receptor 1 (formerly
CD35) gene appeared to be protected (OR  0.3, 95% CI  0.1−0.8, P = 0.02). Borderline evidence for association with
leprosy susceptibility was found for seven polymorphic sites in an additional six genes. Some of these apparent asso-
ciations may be false-positive results from multiple comparisons, and several associations suggested by studies in other
populations were not replicated here. These data provide evidence of inter-population heterogeneity in leprosy suscep-
tibility.
INTRODUCTION
Leprosy is a chronic disabling disease attributable to infec-
tion with Mycobacterium leprae. It has a broad clinical spec-
trum: at one pole is paucibacillary (PB) leprosy, characterized
by a low bacterial count, strong cell-mediated immunity, and
localized disease. At the other pole, multibacillary (MB) lep-
rosy is characterized by a high bacterial count, poor cell-
mediated immunity and strong humoral immunity, with pro-
gressive and disseminated disease. The natural history of lep-
rosy is poorly understood, but family studies, segregation
analyses, and twin studies provide evidence that, in addition
to environmental and exposure factors, host genetic factors
influence leprosy susceptibility.1–4
Elucidation of genetic determinants of host susceptibility to
leprosy could facilitate the development of better preventa-
tive and therapeutic strategies. The earliest strong evidence
pointed towards the major histocompatibility complex region
on chromosome 6.5,6 More recently susceptibility loci have
been mapped using linkage analysis of multi-case families to
chromosomes 10p13 and 20p12 in populations in south India
and to chromosome 6q25 and, again, 10p13, in Vietnam.4,7,8
The linkage on chromosome 10p13 appears to be mainly with
tuberculoid leprosy and the chromosome 6q25 linkage with
leprosy per se. Association studies in various populations
have indicated that several other non-HLA genes may also
influence either leprosy susceptibility or the type of leprosy
that develops upon infection.3 In general, these association
studies have been carried out on relatively small sample sizes,
and some of the reported associations may represent chance
findings, particularly in studies that examined numerous vari-
ants of multiple genes. A major objective of the present study
was to re-evaluate reported associations in an independent
population.
The Karonga Prevention Study (KPS), a long-term epide-
miologic study of mycobacterial disease in the Karonga Dis-
trict of northern Malawi, provides an excellent opportunity to
attempt to replicate previously reported leprosy associations
as well as to investigate de novo hypotheses. A case-control
association study was thus designed to investigate a large
number of putative susceptibility genes (38 polymorphisms
from 13 genes) in this population. The genotyping was per-
formed blind to the disease status of the samples.
Polymorphisms in tumor necrosis factor (TNF, formerly
TNF), the vitamin D receptor (VDR), toll-like receptor 2
(TLR2), and lymphotoxin alpha (LTA, formerly TNF) are
associated with leprosy in other populations and were in-
cluded here in an attempt to replicate these findings.3 An
interleukin-10 (IL10) promoter that has recently been sug-
gested to be associated with leprosy susceptibility in Brazil,
and other polymorphisms that may influence expression of
the immunomodulatory genes IL10 and TLR2 were included
(Segal S and others, unpublished data).9 Polymorphisms in
the genes encoding solute carrier family 11, member 1
(SLC11A1, formerly NRAMP1), mannose-binding lectin
(MBL2, formerly MBP or MBL) and interferon- (IFNG)
were investigated because they have been reported to be as-
sociated, in at least one population, with susceptibility to a
related mycobacterial disease, tuberculosis.10 The toll-like re-
ceptor 4 (TLR4), IL10, and intercellular adhesion molecule 1
(ICAM-1, formerly CD54) loci contain polymorphisms that
are associated with susceptibility to other infectious diseases,
and it was speculated that these genes might represent gen-
eral infectious disease susceptibility loci.11–13 The caspase re-
cruitment domain family, member 15 (CARD15, formerly
NOD2) and CR1 were selected as functional candidates be-
cause of their roles in innate immunity and potential role in
mycobacterial disease. The chemokine (C-C motif) ligand 3
(CCL3, formerly MIP1) was selected as a functional candi-
date due to its involvement in T helper cell 1 (TH1) differ-
entiation.
METHODS
The study protocol was approved by the National Health
Sciences Research Committee of Malawi and by the Ethics
Committee of the London School of Hygiene and Tropical
Medicine.
Recruitment and sample collection. Cases were ascer-
tained within the context of the KPS, a long-term epidemio-
logic study of mycobacterial disease in the Karonga District,
a rural area of northern Malawi. The population and basic
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field methods of the KPS have been described in detail else-
where.14,15 Leprosy cases were identified in the context of
total population surveys during the 1980s, and through “en-
hanced” passive detection (examination of all individuals who
appeared at health centers) in the 1990s, in addition to self-
reporting. Individuals were examined first by paramedical
leprosy control assistants (LCAs), and suspects referred to
project Medical Officers for review examination and (4-mm
punch) biopsy. Diagnostic certainty was defined in terms of
clinical, skin slit smear, and histopathologic data.16 Cases
were defined as PB or MB based upon an algorithm that took
into account all clinical, bacteriologic (slit skin smear), biopsy,
and historical record information. The algorithm implies a
conservative definition of MB (e.g., biopsy or slit skin smear
bacterial index > 1).
Recruitment for this study began in 1996. Since leprosy
incidence had decreased dramatically in the district, cases
were selected retrospectively from project data files. Only
cases that met strict diagnostic criteria were included (N and
M categories as stipulated elsewhere16). Individuals were eli-
gible for selection as controls if they were resident in the
district during the 1986−1989 population survey, and had no
history of either tuberculosis or leprosy. Controls were
matched to cases by age (15−19, 20−24, 25−29, 30−34, 35−44,
45−54, 55−64, and > 65 years old), sex, and geographic area
(residence within 1 km of the case). First- or second-degree
relatives of cases were not eligible for selection as controls.
Each case was matched to up to three controls.
Cases and controls were visited in their homes by field
teams consisting of an LCA and an interviewer. After having
the study explained to them, those who consented were ex-
amined and invited to provide a blood or saliva sample for
genetic testing (those who were willing to provide blood were
told their blood group, and offered syphilis tests with treat-
ment and also human immunodeficiency virus [HIV] coun-
seling and testing if they so desired). All cases ascertained
since 1987 have been offered voluntary counseling and HIV
testing at the time of initial registration as part of a continu-
ous case control study of leprosy, tuberculosis, and HIV.17
Blood (7.5 mL) was collected into EDTA and placed in vac-
cine carriers with wet ice until it reached the project labora-
tory within three days of collection, where cells were sepa-
rated and stored at −70°C. The DNA was separated using
Nucleon kits (Scotlab, Coatbridge, United Kingdom) follow-
ing the manufacturer’s instructions, and shipped at 4°C to the
Wellcome Trust Center for Human Genetics in Oxford,
United Kingdom for analysis.
Genotyping. Genotyping was performed blind to disease
status. A variety of genotyping methods were used to in-
vestigate 38 polymorphisms from 13 candidate genes
(Tables 1 and 2). Four CARD15 polymorphisms were geno-
typed using polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP), the IFN- +874 single
nucleotide polymorphism (SNP) was typed using amplifica-
tion refractory mutation system PCR, and the CARD15 and
IFNG products were analyzed using agarose gel electropho-
resis.18,19 Seven polymorphisms in SLC11A1, LTA, CCL3,
and TLR2 were genotyped by fluorescence PCR followed by
electrophoresis and detection using an ABI fluorescent DNA
sequencer (Applied Biosystems, Foster City, CA) as de-
TABLE 1
Oligonucleotides and conditions used for non-LDR genotyping*
Gene
Location, polymorphism
Amino acid change
(Restriction enzyme)
Genotyping method
(% agarose gel) PCR primers
PCR temperature
product length
CARD15
(NOD2)
Exon 4, 802C→T PCR-RFLP F: CAGTCTCGCTTCCTCAGTACC 55°C
P268S (Bam HI) (3%) R: AGTGTCCGCATCGTCATTG 187 bp
Exon 4, 2104C→T PCR-RFLP F: TTCCTGGCAGGGCTGTTGTCCtGG 55°C
R702W (Msp I) (3%) R: GGATGGAGTGGAAGTGCTTG 139 bp
Exon 8, 2722G→C PCR-RFLP F: AGGCCACTCTGGGATTGAG 55°C
G908R (Hha I) (3%) R: GTGATCACCCAAGGCTTCAG 196 bp
Exon 11, 3020insC PCR-RFLP F: GGCAGAAGCCCTCCTGCAGGgCC 55°C
1007fs (Apa I) (4%) R: CCTCAAAATTCTGCCATTCC 152 bp
CCL3 Promoter, microsatellite Fluorescence PCR F: FAM-AAGGCATGTATTTCCAAGC 58°C
(MIP1-) (TA)n at −906 R: CTGACCCAGCATCGTTTA 327–337 bp
IFNG Intron 1 ARMS PCR IFNGT: TTCTTACAACACAAAATCAAATCT 62°C, 50°C
874T→A (2%) IFNGA: TTCTTACAACACAAAATCAAATCA 461 bp
IFNGCOM: TCAACAAAGCTGATACTCCA
HGHF: GCCTTCCCAACCATTCCCTTA
HGHR: TCACGGATTTCTGTTGTGTTTC 426 bp
LTA 5UTR, microsatellite Fluorescence PCR F: GCCTCTAGATTTCATCCAGCCACAG 58°C, 50°C
(TNF-) (AC/GT)n at −3.5 kb R: HEX-CCTCTCTCCCCTGCAACACACA 93–119 bp
SLC11A1
(NRAMP1)
Promoter, microsatellite Fluorescence PCR F: FAM-TTCTGTGCCTCCCAAGTTAGC 52°C
(GT)n R: ACTCGCATTAGGCCAACGAG 180–220 bp
Exon 2, Fluorescence PCR F: GTGACAAGGGTCCCCAA 60°C
9 bp del R: TET-CGGTTTTGTGTCTGGGAT 143, 132 bp
3 UTR, Fluorescence PCR F: GCATCTCCCCAATTCATGGT 60°C
TGTG ins/del R: TET-AACTGTCCCACTCTATCCTG 240, 244 bp
3 UTR Fluorescence PCR F: TET-CCTAGCGCAGCCATGTGATTACCC 58°C
CAAA ins/del R: AGCCTGTGTCCCGCCCAAGTCCT 234, 238 bp
TLR2 Intron 2, Fluorescence PCR F: TATCCCCATTCATTCGTTCCATT 58°C
microsatellite R: FAM-ACCCCCAAGACCCACACC 213–243 bp
* LDR  ligation detection reaction; PCR  polymerase chain reaction; CARD15  caspase recruitment family, member 15; RFLP  restriction fragment length polymorphism; bp 
basepairs; CCL3  chemokine (C-C motif) ligand 3: IFNG  interferon-; ARMS  amplification refractory mutation system; LTA  lymphotoxin ; UTR  untranslated region; TNF-
 tumor necrosis factor ; SLC11A1  solute carrier family 11, member 1; del  deletion; ins  insertion; TLR2  toll-like receptor 2; fs  frameshift.
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scribed later in this report (Segal S and others, unpublished
data).20,21 The PCR primers, conditions, and restriction en-
zymes used are shown in Table 1.
Direct sequence analysis. Direct sequence analysis was
used to determine whether the TLR2 R677W, R753Q, and
CARD15 R790Q variants were present in the Malawi popu-
lation13,22 (National Center for Biotechnology Information
SNP database, Bethesda, MD). The PCR primers and ther-
mocycles were TLR2 exon 3 586-basepair (bp) segment: 5-
gcgtggccagcaggttcag-3, 5-gggccactccaggtaggtcttg-3 (ther-
mocycles: one cycle at 94°C for four minutes; 36 cycles at 94°C
for 30 seconds, 58°C for 40 seconds, and 72°C for 60 sec-
onds; and one cycle at 72°C for two minutes) and CARD15
exon 4 509-bp segment: 5-gccgagccgcacaacctt-3, 5-gtgct-
cccccatacctgaaca-3 (thermocycles: one cycle at 94°C for five
minutes; 35 cycles at 60°C for 30 seconds, and 72°C for 45
seconds; and one cycle at 72°C for four minutes). The PCR (2
× 25 L) and sequencing (20 L) reaction were performed
using standard conditions. Sequence analysis was performed
using an ABI 3700 fluorescent DNA sequencer. Each seg-
ment was sequenced in both directions.
Genotyping using the post-PCR multiplexed ligation detec-
tion reaction (LDR). The LDR was used to genotype the
remaining 23 SNPs located in seven genes.23 Briefly, frag-
ments containing the SNPs of interest were PCR-amplified
using appropriate primers and conditions (Table 2). Amplifi-
cations were performed in a total volume of 15 L and con-
tained 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1−2.5 mM
MgCl2, 200 M of each dNTP, 0.2 M of each primer, ap-
proximately 50 ng of DNA, and 0.5 units of Amplitaq Gold
polymerase (Perkin-Elmer, Boston, MA). To prevent poly-
merase extension during the subsequent LDR procedure, re-
sidual polymerase activity was removed by incubation with
1:10 volume of 1 mg/mL of proteinase K in 50 mM EDTA at
37°C for 30 minutes and 55°C for 10 minutes. The proteinase
K was inactivated by incubation at 99°C for 10 minutes.
A set of three probes consisting of two fluorescently la-
beled allelic and one common probe was designed for each of
the SNPs investigated using the LDR (Table 2). The common
probes (100 pmol of each) were 5 phosphorylated in a vol-
ume of 100 L using 10 units of T4 polynucleotide kinase and
1 mM ATP in 70 mM Tris-HCl buffer, pH 7.6, containing 10
mM MgCl2 and 5 mM dithiothreitol. After incubation at 37°C
for 45 minutes, the T4 kinase was inactivated by the addition
of 20 g of proteinase K in 100 L of TE buffer (10 mM
Tris-HCl, 5 mM EDTA, pH 8.0) and incubating at 37°C for 30
minutes. The proteinase K was inactivated by incubation at
99°C for 10 minutes.
The multiplexed LDR was performed in 15-L volumes of
20 mM Tris-HCl buffer, pH 7.6, containing 25 mM KCl, 10
mM MgCl2, 1 mM NAD
+, 10 mM dithiothreitol, 0.1% Triton
X-100, 10 nM (200 fmol) of each LDR probe, 2 L of PCR
product, and 2 units of Taq DNA ligase. The reactions were
prepared on ice and then initiated by placing on PCR blocks
pre-heated to 95°C. An initial one-minute denaturation at
95°C was followed by 15 thermal cycles of denaturation at
95°C for 15 seconds, and annealing and ligation at the appro-
priate temperature (Table 2) for four minutes. The activity of
the ligase was stopped after 15 cycles by cooling to 4°C and
adding 2 L of 100 mM EDTA.
Electrophoresis and detection of multiplexed and/or
pooled LDR or fluorescent PCR products was performed on
an ABI 373 or ABI 3700 fluorescent DNA sequencer. For the
ABI 3700, 1 L of LDR product was added to 10 L of Hi-Di
formamide and 0.01 L of 8 nM ABI Genescan-500 Rox size
standards (Applied Biosystems). For the ABI373, 2 L of
LDR product was added to 1.5 L of 5:1 deionized formam-
ide, 25 mM EDTA with blue dextran (1 mg/mL), and 0.5 L
of fluorescently labeled size standards (GeneScan-350 tetra-
methylrhodamine [TAMRA]). After denaturation, the prod-
uct was subjected to electrophoresis on 6% polyacrylamide
gels. Product sizes were calculated relative to the standard
with Genescan 3.5 (Perkin Elmer Applied Biosystems, War-
rington, United Kingdom) using the second order least
squares method. Automated allele calling of LDR products
was performed using Genotyper 2.5 (Perkin Elmer Applied
Biosystems).
Statistical analysis. For each polymorphism, the percent-
age of individuals with a particular genotype was calculated
separately for cases and controls. Conditional logistic regres-
sion was used to quantify the association between disease and
genotype, with and without controlling for ethnic group, and
with and without restriction to PB cases. The percentage of
cases with a particular genotype was also calculated sepa-
rately for PB and MB cases.
RESULTS
Recruitment. A total of 334 cases and 702 controls were
selected from the database and sought in the field. Of the 334
cases, 22 had left the district and 34 had died by the time they
were sought for genetics testing, 7 were alive but neither a
blood nor a buccal swab specimen were provided, and for one
case data were not available for a matched control. This gave
a total of 270 cases that could be included in analyses, 26 of
which were MB. Of the 702 controls that were sought, 74 had
left the district and 90 had died by the time they were sought
for genetics testing, 26 were alive but neither a blood nor a
buccal swab specimen were provided, and for 60 data on the
matched case were not available. Thus, 452 controls were
included in these analyses. There were one or two controls for
each case. Blood specimens were available for all except eight
individuals, who provided buccal swabs.
Direct sequence analysis. Sequence analysis of 83 individu-
als (including cases and controls) indicated that the TLR2
R677W and R753Q variants were not present, or were very
rare, in northern Malawi. Likewise, the CARD15 SNP
R790Q was not found upon sequencing of 63 individuals. Ac-
cordingly, further genotyping of these SNPs was not per-
formed.
Genotyping results. The PCR-RFLP analysis of more than
150 Malawians indicated that the CARD15 variants P268S,
R702W, G908R, and 1007fs were not present in this popula-
tion. The TNF-1031 variant was also not found. The MBL2
R52C, MBL2 G54D, TNF + 70, and −857 variants were very
rare in Karonga District, occurring with an allele frequency of
< 1.0%. No homozygotes of these variants were identified.
Association study results for leprosy susceptibility. The ge-
notype frequencies and odds ratios (ORs) of the 26 variants
that were sufficiently polymorphic for leprosy association
analysis are shown in Table 3, with ORs controlled for ethnic
group. The results shown combine PB and MB cases, but all
results were unchanged when restricted to PB cases. For most
polymorphisms, there was no evidence of an association with
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TABLE 3
Genotype frequencies for all leprosy (paucibacillary and multibacillary)* cases and controls, and odds ratios (ORS) controlled for age, sex, area
of residence, and ethnic group†
Gene Polymorphism Genotype
Case Control
OR
(95% confidence interval)% n % n
CCL3
(MIP1-)
Promoter microsatellite
(TA)n at –906
331/331 41 54 46 131
331/327 31 40 25 71 1.4 (0.7–2.7), P  0.37
331/333 16 21 18 52 0.9 (0.4–2.0), P  0.79
Other 12 16 11 31 1.0 (0.4–2.9), P  0.94
131 285 (110, 146)‡
CR1 Exon 19 g/g 79 131 81 151
3093G→T g/t 20 33 17 31 1.1 (0.5–2.1), P  0.86
Q1022H t/t 1 2 2 4 0.4 (0.06–2.6), P  0.33
166 186 (136, 136)
Exon 28 a/a 65 164 60 238
4795A→G a/g 32 80 34 135 0.8 (0.5–1.1), P  0.18
K1590E g/g 3 7 6 26 0.3 (0.1–0.8), P  0.02
(McCa→McCb) 251 399 (245, 374)
Exon 29 g/g 45 114 49 196
4828G→A g/a 45 114 40 157 1.3 (0.9–1.9), P  0.12
R1601G a/a 10 24 11 42 1.0 (0.5–1.9), P  0.99
(Sl1→Sl2) 252 395 (246, 371)
Exon 29 g/g 76 192 79 311
4870A→G g/a 23 57 20.5 81 1.3 (0.9–2.0), P  0.21
I1615V a/a 1 3 0.5 2 1.7 (0.3–11.1), P  0.58
252 394 (246, 370)
Exon 33 c/c 71 128 79 172
5507C→G c/g 28 51 18 40 1.4 (0.8–2.5), P  0.21
P1827R g/g 1 2 3 7 0.2 (0.01–1.7), P  0.12
181 219 (153, 168)
ICAM1 Exon 2 a/a 54 112 55 134
179A→T a/t 32 68 31 76 1.1 (0.6–1.7), P  0.83
K29M t/t 14 29 14 35 1.0 (0.5–2.0), P  0.93
(ICAM-1ref→ICAM-1Kilifi) 209 245 (189, 208)
IFNG Intron 1 a/a 67 157 66 265
874T→A a/t 28 67 27 109 1.1 (0.7–1.6), P  0.72
t/t 5 12 7 28 0.8 (0.4–1.8), P  0.59
236 402
IL10 Promoter c/c 46 97 43 157
−592C→A c/a 38 81 47 169 0.7 (0.5–1.1), P  0.13
a/a 16 34 10 36 1.7 (1.0–3.3), P  0.06
212 362 (203, 296)
Promoter c/c 44 95 42 147
−819C→T c/t 41 88 48 170 0.8 (0.5–1.2), P  0.23
t/t 15 32 10 36 1.6 (0.9–3.0), P  0.11
215 353 (204, 293)
Promoter a/a 45 86 43 149
−1082A→G a/g 44 84 44 154 1.0 (0.6–1.5), P  0.96
g/g 11 21 13 46 0.7 (0.4–1.4), P  0.30
191 349 (183, 262)
LTA 5UTR microsatellite 101 absent 89 164 89 296
(TNF-) (AC/GT)n at −3.5 kb§ 101 1 copy 10 18 11 36 0.9 (0.5–1.7), P  0.80
101 2 copies 1 2 0.3 1
184 333
103 absent 52 96 59 196
103 1 copy 45 83 36 121 1.2 (0.8–1.8), P  0.42
103 2 copies 3 5 5 16
184 333
105 absent 49 90 58 192
105 1 copy 42 78 37 124 1.6 (1.1–2.4), P  0.03
105 2 copies 9 16 5 17
184 333
111 absent 95 174 90 301
111 1 copy 5 10 10 32 0.4 (0.2–1.1), P  0.07¶
111 2 copies 0 0 0 0
184 333 (163, 228)
MBL2 Exon 1 g/g 63 146 65 169
(MBL) 239G→A g/a 32 73 30 78 1.1 (0.7–1.7), P  0.63
G57E (C variant) a/a 5 12 5 14 0.9 (0.4–2.1), P  0.73
231 261 (224, 238)
LEPROSY SUSCEPTIBILITY IN THE KARONGA DISTRICT OF MALAWI 335
TABLE 3
Continued
Gene Polymorphism Genotype
Case Control
OR
(95% confidence interval)% n % n
SLC11A1 Promoter microsatellite 199/199 63 158 56 237
(NRAMP1) (GT)n 199/201 30 75 36 153 0.7 (0.5–1.0), P  0.06
(199  allele 3, 201  allele 2) 201/201 4 11 6 25 0.6 (0.3–1.4), p  0.24
Other 2 5 2 8 1.4 (0.4–4.3), P  0.60
249 423 (247, 388)
Exon 2 Ins/ins 93 228 91 258
9 bp del del present 7 16 9 25 0.7 (0.3–1.4), P  0.31
244 283 (236, 261)
3UTR Ins/ins 47 122 50 203
TGTG ins/del Ins/del 43 112 41 164 1.1 (0.8–1.5), P  0.64
del/del 9 24 9 35 1.2 (0.7–2.1), P  0.58
258 402 (248, 391)
3UTR del/del 41 106 45 192
CAAA ins/del Ins/del 45 117 44 191 1.1 (0.8–1.6), P  0.48
Ins/ins 14 35 11 46 1.5 (0.9–2.6), P  0.14
258 429 (257, 410)
TLR2 Intron 2 microsatellite# 216 absent 90 188 88 332
216 1 copy 10 22 12 45 0.7 (0.4–1.3), P  0.25
216 2 copies 0 0 0.5 2
210 379
222 absent 78 164 79 299
222 1 copy 21 44 19 74 0.9 (0.6–1.5), P  0.73
222 2 copies 1 2 2 6
210 379
224 absent 37 78 40 151
224 1 copy 52 108 50 188 1.0 (0.7–1.4), P  0.91
224 2 copies 11 24 10 40
210 379
226 absent 76 160 74 279
226 1 copy 21 44 24 92 0.9 (0.6–1.4), P  0.68
226 2 copies 3 6 2 8
210 379 (194, 286)
TLR4 Exon 4 a/a 95 223 91 262
896A→G g/a 5 12 9 25 0.5 (0.2–1.1), P  0.08
D299G g/g 0 0 0.4 1
235 288 (243, 383)
TNF Promoter g/g 85 206 84 237
−238G→A g/a 15 36 15 43 0.9 (0.5–1.5), P  0.71
a/a 0.4 1 1 3 1.4 (0.1–16.6), P  0.80
243 283 (235, 262)
Promoter g/g 80 173 78 201
−308G→A g/a 19 42 20 51 1.5 (0.9–2.5), P  0.15
(TNF*1→TNF*2) a/a 1 1 2 6 0.2 (0.02–1.8), P  0.15
216 258 (195, 223)
Promoter g/g 88 211 86 242
−376G→A g/a 11 27 13 38 0.8 (0.4–1.4), P  0.37
a/a 0.4 1 1 2 1.3 (0.1–15.8), P  0.83
239 282 (231, 257)
Promoter c/c 75 177 75 212
−863C→A a/c 22 51 24 68 0.9 (0.6–1.5), P  0.77
a/a 3 8 1 3 4.0 (0.8–19.7), P  0.09
236 283 (228, 254)
VDR Intron 8 t/t 50 85 45 147
G→T t/g 43 73 48 158 0.7 (0.5–1.2), P  0.21
(Apa I; a→A) g/g 7 11 7 23 1.5 (0.6–4.0), P  0.43
169 328 (159, 235)
Intron 8 c/c 62 104 60 197
C→T c/t 28 47 35 115 0.8 (0.5–1.3), P  0.35
(Bsm I; b→B) t/t 10 17 5 18 2.1 (0.9–5.0), P  0.08
168 330 (158, 235)
Exon 9 t/t 53 131 57 228
T→C (codon 352) t/c 41 101 40 158 1.1 (0.8–1.7), P  0.54
(Taq I; T→t) c/c 6 15 3 12 4.3 (1.6–11.4), P  0.004
247 398 (240, 375)
* The results did not change when analysis was restricted to paucibacillary cases and their matched controls.
† For definitions of abbreviations, see Tables 1 and 2.
‡ The number of cases and controls used in the logistic regression.
§ ORs are for one copy of the allele, and are with respect to baseline of pairs of alleles not including any of 101, 103, 105, and 111.
¶ P  0.03, test for heterogeneity among LTA alleles.
# ORs are for one copy of the allele, and are with respect to baseline of pairs of alleles not including any of 216, 222, 224, and 226.
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leprosy susceptibility; however, for TNF −376 and −238, the
95% confidence intervals (CIs) were too wide to eliminate
this. The polymorphisms ICAM1 K29M, MBL2 G57E,
SLC11A1 exon 2 9-bp deletion, TGTG insertion/deletion,
CAAA insertion/deletion, CR1 R1601G, IFNG +874, CCL3
microsatellite, TLR2 intron 2 microsatellite, and IL10 -1082
were not found to be associated with leprosy susceptibility.
Borderline evidence of association with leprosy susceptibility
was found for six polymorphisms: TNF −863, SLC11A1 pro-
moter microsatellite, IL10 −592, TLR4 D299G, VDR Bsm I,
and the LTA microsatellite 111-bp allele. Two SNPs were
found to be associated with leprosy susceptibility with a 5%
level of statistical significance without correcting for multiple
comparisons: homozygotes (tt) for a silent T→C change in
codon 352 of the VDR gene are susceptible (OR  4.3, 95%
CI  1.6−11.4, P = 0.004), while homozygotes for the CR1
variant K1590E are protected (OR  0.3, 95% CI  0.1−0.8,
P  0.02). Presence of the LTA microsatellite 105-bp allele,
but not the overall distribution of alleles at this microsatellite
locus, was also associated with leprosy susceptibility (OR 
1.6, 95% CI  1.1−2.4, P = 0.03).
Association study results for leprosy type. Comparison of
genotype frequency between MB and PB cases usually indi-
cated no differences. However, there was suggestive evidence
that presence of the LTA 101-bp microsatellite allele is asso-
ciated with MB leprosy (2  11.4, P  0.003) and borderline
evidence that the TLR2 224-bp microsatellite allele (2  6.3,
P  0.042) genotype frequencies may differ between leprosy
types. However, since only 26 MB cases were included in this
study these results could be due to sampling error.
DISCUSSION
Of the 38 polymorphisms investigated, 12 were insuffi-
ciently polymorphic for analysis and 2 showed evidence of
association with leprosy susceptibility in this population.
These two are discussed first.
The nuclear hormone receptor VDR mediates the many
immunomodulatory effects of the active form of vitamin D
(125(OH)2D3), which include suppression of cytokine syn-
thesis, immunoglobulin production, and lymphocyte prolif-
eration. Epidemiologic evidence suggests that vitamin D de-
ficiency may be associated with susceptibility to tuberculosis
and vitamin D impairs growth of M. tuberculosis in human
macrophage and monocytic cell lines, while vitamin D-
containing medications have been useful in treating some lep-
rosy cases.10,24 Homozygosity for a Taq I polymorphism (tt)
in the ligand binding domain of VDR was associated with PB
leprosy in Bengali Indians and resistance to tuberculosis in
The Gambia.10,25 In the Bengali leprosy study the TT geno-
type was associated with MB leprosy and the Tt genotype was
associated with leprosy susceptibility per se. In Karonga,
where the leprosy cases are predominantly (90%) PB, the tt
genotype was associated with susceptibility to leprosy per se.
However, the apparent association in Karonga should be in-
terpreted with caution. The expected frequency of tt homozy-
gotes based on the measured t allele frequency in controls is
5%. The observed frequency in cases is 6% and in controls
3%. Thus, much of the apparent difference relates to a de-
viation of the control frequency from Hardy-Weinberg equi-
librium, which may be a chance finding. In Mali, no associa-
tion was found for the VDR genotype with either leproma-
tous or tuberculoid leprosy or leprosy per se (Meisner S,
unpublished data). It is not clear whether the silent T/t poly-
morphism has a direct effect on function or expression of
VDR, and it seems more likely that reported disease associa-
tions, if real, relate to linkage disequilibrium with a flanking
functional polymorphism.26,27
On phagocytic cells, CR1 mediates the adherence and
phagocytosis of complement-opsonized pathogens. Since M.
leprae and M. tuberculosis can both gain entry into macro-
phages using this mechanism, it was hypothesized that vari-
ants in CR1 may influence susceptibility to mycobacterial dis-
ease.28,29 Five polymorphisms that encode amino acid
changes in the extracellular domains of the protein and may
affect either ligand binding or CR1 stability were investi-
gated.30,31 These included the variants K1590E and R1601G,
which under l ie the Knops b lood group McCoy
(McCa→McCb) and Swain-Langley (Sl1→Sl2) polymor-
phisms, respectively. Both the McCb and Sl2 alleles are more
prevalent in African populations than in Caucasian, Asian, or
Hispanic Americans, and it has been suggested that they may
confer a selective advantage against infectious disease.32
These alleles were less common in Malawi (McCb  0.23, Sl2
 0.31) than in the west African Gambian population (McCb
 0.39, Sl2  0.80), but more common than in non-African
populations (McCb  0.025, Sl2  0.03). Homozygosity for
the McCb allele was associated with protection against lep-
rosy in Malawi; however, the biologic mechanism underlying
this finding is unclear.
Four other genes, TNF, LTA, IL-10, and TLR2, which have
been reported to be associated with leprosy susceptibility
elsewhere, failed to show association of the relevant polymor-
phisms in Karonga.3
The proinflammatory cytokine TNF influences several as-
pects of the immune response, including macrophage activa-
tion (important for killing of mycobacteria) and granuloma
formation (important for containment of mycobacterial infec-
tions), and can also cause tissue damage and apoptosis. Sev-
eral promoter polymorphisms exist which may be involved
in regulation of TNF expression and such variants have
been associated with both autoimmune and infectious dis-
eases.33–35 A G→A polymorphism (TNF*2) at −308, which
may be associated with increased TNF expression, was
strongly linked to and associated with resistance to leprosy in
Brazil.6,9,36,37 Contrary to these findings, the same variant has
been associated with MB leprosy susceptibility in Bengali In-
dians, indicating, perhaps, that different aspects of TNF may
be important in controlling the outcome of leprosy infection
in different populations, perhaps due to the presence of dif-
ferent M. leprae strains, or a modified cytokine milieu result-
ing from presence of varying infectious pathogens or differ-
ences in genetic backgrounds.38 We found no evidence that
the −308 variant has a role in leprosy susceptibility in Malawi.
Six other TNF polymorphisms were investigated in this study,
but the −1031, +70 and −857 variants were very rare and thus
could not be tested for any association. There was no evi-
dence that the −376 polymorphism, which upregulates TNF
expression by introducing a binding site for the OCT-1 tran-
scription factor, and is associated with severe malaria, was
associated with leprosy susceptibility in Malawi, although the
confidence limits were too wide to eliminate this possibility.33
Consistent with a recent Brazilian leprosy study, the −238
LEPROSY SUSCEPTIBILITY IN THE KARONGA DISTRICT OF MALAWI 337
SNP, which may produce increased TNF transcription, was
not found to be associated with leprosy in Malawi.9,39 The
−863 SNP is located in an NF-B regulatory site and results in
reduced p50-p50 enhancement of expression.40 There was
borderline evidence that this variant may be associated with
leprosy susceptibility in Malawi, which is consistent with the
findings that higher levels of TNF production may be protec-
tive against leprosy in Brazil.
Located close to the TNF gene, LTA encodes a cytokine
that is produced by lymphocytes and natural killer cells and
which has pleiotropic immunomodulatory effects. A haplo-
type that includes an intronic LTA SNP is associated with
leprosy susceptibility in Brazil.6 In Malawi, the 105-bp allele
may be weakly associated with leprosy susceptibility, while
the 101-bp allele may influence leprosy type. It is possible that
these associations are due to linkage disequilibrium with
other polymorphisms either in another gene in the HLA re-
gion, or within LTA, or they may just be chance findings.20
However, further investigation of possible associations, if any,
between LTA and susceptibility both to leprosy per se, and to
leprosy type is warranted.
The cytokine IL10 has pleiotropic effects in immunoregu-
lation and inflammation, including the inhibition of TH1 cy-
tokine secretion and T cell proliferation. Polymorphisms in
the promoter influence the amount of IL10 production.10,41,42
It was speculated that by suppressing inflammation, high
IL10 production might increase mycobacterial susceptibility.
Three promoter polymorphisms in IL10 were investigated in
Malawi and borderline evidence was found that homozygotes
for the −592 A variant may have increased susceptibility to
leprosy. Recently, the -819 T variant has been reported to be
weakly associated with leprosy susceptibility in Brazil.9 These
two variants exhibit linkage disequilibrium and usually occur
together on a haplotype (−1082 A, −1892 T, −592 A) that is
associated with increased IL10 production. In Brazil, homozy-
gosity for the −592 A variant is not significantly associated
with susceptibility, but there is a trend in this direction. Thus,
it is possible that the ATA haplotype may be associated with
leprosy susceptibility in both these populations but much
larger studies would be required to assess this.
Mammalian toll-like receptors recognize and react to a va-
riety of bacterial cell wall components to activate direct an-
timicrobial mechanisms and to facilitate transcription of
genes that regulate the adaptive inflammatory immune re-
sponse. TLR2, probably acting as a heterodimer with other
TLRs, recognizes components from a variety of microbial
pathogens including mycobacterial lipoproteins and lipoara-
binomannan. Mycobacterium leprae can activate both TLR2-
TLR1 heterodimers and TLR2 homodimers.43 TLR4 is the
receptor for lipopolysaccharide (LPS), a major cell wall com-
ponent of gram-negative bacteria, but it seems that both
TLR2 and TLR4 can mediate cellular activation in response
to components of gram-positive Mycobacterium tuberculo-
sis.44 An Arg299Gly polymorphism in the extracellular do-
main results in impaired TLR4-mediated LPS induced signal-
ing.45 Heterozygosity is associated with hypo-responsiveness
to inhaled LPS, Thus, it appears counter-intuitive that al-
though only borderline significant, heterozygosity for the rare
299Gly allele was increased among controls.46 It would be of
interest to determine whether this genotype is associated with
protection in other populations.
Three TLR2 polymorphisms were also investigated. Se-
quencing indicated that Arg677Trp and Arg753Gln, identi-
fied as rare variants in other populations, are extremely rare
in Malawi and variation in a microsatellite located in intron 2
of the TLR2 gene was not associated with leprosy suscepti-
bility.13,22
Mannose-binding lectin binds to mannose and N-
acetylglucosamine groups on a variety of bacteria, resulting in
complement activation and opsonophagocytosis. Any one of
three exon 1 point mutations (R52C, G54D, and G57E) re-
duces serum MBL concentrations. Since low serum levels of
MBL may be associated with recurrent infections in young
children and yet low-producing alleles are maintained in all
populations, as for ICAM1, it has been proposed that bal-
ancing selection might exist.47 One hypothesis is that low
MBL levels may protect against mycobacterial disease by lim-
iting phagocytotic entry of mycobacteria into host cells.48
Consistent with studies of other African populations, the
R52C and G54D polymorphisms were found only rarely in
Malawi. The G57E (C) variant had an allele frequency of
20% and was not associated with leprosy susceptibility.
Interferon- is an essential and central regulator of the
human response to infection. The intronic +874 T/A SNP lies
in a putative binding site for the transcription factor NF-B.
The T allele, which may be associated with high IFN- pro-
duction has recently been found to be associated with resis-
tance to tuberculosis in Sicilians and South Africans.10,19,49,50
This SNP has not previously been investigated for an asso-
ciation with leprosy susceptibility and was not found to be
associated with leprosy in Malawi. This could be because the
lower allele frequency in Malawi (20% compared with 50%)
reduces the power to detect such an association because the
tuberculosis association is due to another polymorphism that
is in linkage disequilibrium with the +874 SNP in Sicily but
not in Malawi, or because this allele does not affect leprosy
susceptibility in this population.
The SLC11A1 gene encodes a protein that may have a
direct effect on the survival of mycobacteria within macro-
phage phagosomes, but may also have pleiotropic effects that
include regulation of the TH1:TH2 balance of the adaptive
immune response to infection. Since the mouse homolog
Slc11a1 protects against some mycobacterial infections and
SLC11A1 variants have been associated with human tuber-
culosis susceptibility, SLC11A1 has long been a candidate for
leprosy susceptibility. However, although a haplotype segre-
gation study suggested this gene may influence leprosy sus-
ceptibility in Vietnam,51 other studies have found no evidence
for association and/or linkage with susceptibility.25,51–54 How-
ever, variants of this gene have been associated with leprosy
type in Mali and linked with the size of the Mitsuda response
in southeast Asians.53,55 For three of the four SLC11A1 poly-
morphisms examined in the Malawi population, there was no
evidence of an association with leprosy susceptibility. The
fourth, a promoter microsatellite, showed borderline evi-
dence that the putative lower-expressing allele 201 (allele 2)
may be protective against leprosy in this population. This
contrasts with the reported association of this allele with tu-
berculosis susceptibility in The Gambia.10,56
The aim of this study was to better understand the genetic
factors that underlie host immune responses to leprosy. We
find evidence that variants in the VDR and CR1 genes may
influence leprosy susceptibility in the Karonga District of
northern Malawi, and it is possible that variants of some of
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the others genes studied may also play a minor role. The
sibling risk ratio for leprosy in this population appears to be
of the order of two, and thus the genes and modest associa-
tions studied here appear insufficient to account for the over-
all genetic component identified.57 Therefore, it seems likely
that there are several other host genes that contribute to a
complex network of gene products that may synergize or
counteract each other to influence leprosy susceptibility. In-
teraction of strain, environment, nutrition, presence and na-
ture of concurrent background infections, varying linkage dis-
equilibrium, and allele frequencies may limit the usefulness of
extrapolating these findings to other populations. Indeed, a
major conclusion from this large-scale study is that many of
the associations suggested by studies in other populations are
not found in this Malawian population. Our data urge caution
in the interpretation of infectious disease genetic associations
from single-population analyses and support the re-
assessment of positive findings in replication studies.
Received August 28, 2003. Accepted for publication January 19,
2004.
Acknowledgments: We thank the many field, laboratory, and data
management staff of the KPS who have carried out the leprosy work
in Karonga District since 1979, the people of Karonga District, and
the Ministry of Health and Population and the National Health Sci-
ences Research Committee of Malawi for their encouragement of the
KPS over many years. We also thank past and present Wellcome
Trust Centre for Human Genetics (WTCHG) researchers and col-
laborators including Peter Zimmerman, Patricia Ramaley, and Gra-
ham Cooke for their role in developing the genotyping methods used
here, as well as WTCHG core facilities staff, and Kerrie Tosh, Chris-
tophe Aucan, and Dr. Branwen Hennig, for their assistance.
Financial support: The leprosy work of the KPS has been funded
since its inception by the British Leprosy Relief Association, with
contributions from the International Federation of Anti-Leprosy As-
sociations. This study was supported by the Wellcome Trust. Adrian
V. S. Hill is a Wellcome Trust Principal Research Fellow.
Authors’ addresses: Jodene Fitness, School of Biological Sciences,
Victoria University of Wellington, PO Box 600, Wellington, New
Zealand, E-mail: jodene.fitness@vuw.ac.nz. Sian Floyd and Paul E.
M. Fine, Department of Tropical Hygiene, London School of Hy-
giene and Tropical Medicine, Keppel Street, London WC1E 7HT,
United Kingdom, E-mai ls : s ian . f loyd@lshtm.ac .uk and
paul.fine@lshtm.ac.uk. David K. Warndorff, Lifted Sichali, Lorren
Mwaungulu, and Amelia C. Crampin, Karonga Prevention Study, PO
Box 46, Chilumba, Karonga District, Malawi. Adrian V. S. Hill,
Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Ox-
ford OX3 7BN, United Kingdom, E-mail: adrian.hill@molecular-
medicine.oxford.ac.uk.
REFERENCES
1. Fine PE, 1988. Implications of genetics for the epidemiology and
control of leprosy. Philos Trans R Soc Lond B Biol Sci 321:
365–376.
2. Chakravartti MR, Vogel F, 1973. A twin study on leprosy. Top
Hum Genet 1: 1–123.
3. Fitness J, Tosh K, Hill AV, 2002. Genetics of susceptibility to
leprosy. Genes Immun 3: 441–453.
4. Tosh K, Meisner S, Siddiqui MR, Balakrishnan K, Ghei S,
Golding M, Sengupta U, Pitchappan RM, Hill AV, 2002. A
region of chromosome 20 is linked to leprosy susceptibility in
a south Indian population. J Infect Dis 186: 1190–1193.
5. Todd JR, West BC, McDonald JC, 1990. Human leukocyte an-
tigen and leprosy: study in northern Louisiana and review. Rev
Infect Dis 12: 63–74.
6. Shaw MA, Donaldson IJ, Collins A, Peacock CS, Lins-Lainson Z,
Shaw JJ, Ramos F, Silveira F, Blackwell JM, 2001. Association
and linkage of leprosy phenotypes with HLA class II and tu-
mour necrosis factor genes. Genes Immun 2: 196–204.
7. Siddiqui MR, Meisner S, Tosh K, Balakrishnan K, Ghei S, Fisher
SE, Golding M, Shanker Narayan NP, Sitaraman T, Sengupta
U, Pitchappan R, Hill AV, 2001. A major susceptibility locus
for leprosy in India maps to chromosome 10p13. Nat Genet 27:
439–441.
8. Mira MT, Alcais A, van Thuc N, Thai VH, Huong NT, Ba NN,
Verner A, Hudson TJ, Abel L, Schurr E, 2003. Chromosome
6q25 is linked to susceptibility to leprosy in a Vietnamese
population. Nat Genet 33: 412−415.
9. Santos AR, Suffys PN, Vanderborght PR, Moraes MO, Vieira
LM, Cabello PH, Bakker AM, Matos HJ, Huizinga TW, Ot-
tenhoff TH, Sampaio EP, Sarno EN, 2002. Role of tumor ne-
crosis factor-alpha and interleukin-10 promoter gene polymor-
phisms in leprosy. J Infect Dis 186: 1687–1691.
10. Fitness J, Floyd S, Warndorff DK, Sichali L, Malema S, Crampin
AC, Fine PEM, Hill AVS, 2004. Large-scale candidate gene
study of tuberculosis susceptibility in the Karonga district of
northern Malawi. Am J Trop Med Hyg 70: (in press).
11. Fernandez-Reyes D, Craig AG, Kyes SA, Peshu N, Snow RW,
Berendt AR, Marsh K, Newbold CI, 1997. A high frequency
African coding polymorphism in the N-terminal domain of
ICAM-1 predisposing to cerebral malaria in Kenya. Hum Mol
Genet 6: 1357–1360.
12. Shin HD, Winkler C, Stephens JC, Bream J, Young H, Goedert
JJ, O’Brien TR, Vlahov D, Buchbinder S, Giorgi J, Rinaldo C,
Donfield S, Willoughby A, O’Brien SJ, Smith MW, 2000. Ge-
netic restriction of HIV-1 pathogenesis to AIDS by promoter
alleles of IL10. Proc Natl Acad Sci U S A 97: 14467–14472.
13. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA, 2000.
A novel polymorphism in the toll-like receptor 2 gene and its
potential association with staphylococcal infection. Infect Im-
mun 68: 6398–6401.
14. Ponnighaus JM, Fine PE, Sterne JA, Bliss L, Wilson RJ, Malema
SS, Kileta S, 1994. Incidence rates of leprosy in Karonga Dis-
trict, northern Malawi: patterns by age, sex, BCG status and
classification. Int J Lepr Other Mycobact Dis 62: 10–23.
15. Ponninghaus JM, Fine PE, Bliss L, Sliney IJ, Bradley DJ, Rees
RJ, 1987. The Lepra Evaluation Project (LEP), an epidemio-
logical study of leprosy in northern Malawi. I. Methods. Lepr
Rev 58: 359–375.
16. Ponnighaus JM, Fine PE, Bliss L, 1987. Certainty levels in the
diagnosis of leprosy. Int J Lepr Other Mycobact Dis 55: 454–
462.
17. Ponnighaus JM, Mwanjasi LJ, Fine PE, Shaw MA, Turner AC,
Oxborrow SM, Lucas SB, Jenkins PA, Sterne JA, Bliss L, 1991.
Is HIV infection a risk factor for leprosy? Int J Lepr Other
Mycobact Dis 59: 221–228.
18. van Heel DA, McGovern DP, Cardon LR, Dechairo BM, Lench
NJ, Carey AH, Jewell DP, 2002. Fine mapping of the IBD1
locus did not identify Crohn disease-associated NOD2 vari-
ants: implications for complex disease genetics. Am J Med
Genet 111: 253–259.
19. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV, 2000. A
single nucleotide polymorphism in the first intron of the hu-
man IFN-gamma gene: absolute correlation with a polymor-
phic CA microsatellite marker of high IFN-gamma production.
Hum Immunol 61: 863–866.
20. Jongeneel CV, Briant L, Udalova IA, Sevin A, Nedospasov SA,
Cambon-Thomsen A, 1991. Extensive genetic polymorphism
in the human tumor necrosis factor region and relation to ex-
tended HLA haplotypes. Proc Natl Acad Sci U S A 88: 9717–
9721.
21. Al-Sharif FM, Makki RF, Ollier WE, Hajeer AH, 1999. A new
microsatellite marker within the promoter region of the MIP-
1A gene. Immunogenetics 49: 740–741.
22. Kang TJ, Chae GT, 2001. Detection of Toll-like receptor 2
(TLR2) mutation in the lepromatous leprosy patients. FEMS
Immunol Med Microbiol 31: 53–58.
23. Day DJ, Speiser PW, White PC, Barany F, 1995. Detection of
steroid 21-hydroxylase alleles using gene-specific PCR and a
multiplexed ligation detection reaction. Genomics 29: 152–162.
24. Rogers L, 1921. Chaulmoogra oil in leprosy and tuberculosis.
Lancet 1: 1178–1180.
LEPROSY SUSCEPTIBILITY IN THE KARONGA DISTRICT OF MALAWI 339
25. Roy S, Frodsham A, Saha B, Hazra SK, Mascie-Taylor CG, Hill
AV, 1999. Association of vitamin D receptor genotype with
leprosy type. J Infect Dis 179: 187–191.
26. Verbeek W, Gombart AF, Shiohara M, Campbell M, Koeffler
HP, 1997. Vitamin D receptor: no evidence for allele-specific
mRNA stability in cells which are heterozygous for the Taq I
restriction enzyme polymorphism. Biochem Biophys Res Com-
mun 238: 77–80.
27. Mocharla H, Butch AW, Pappas AA, Flick JT, Weinstein RS, De
Togni P, Jilka RL, Roberson PK, Parfitt AM, Manolagas SC,
1997. Quantification of vitamin D receptor mRNA by com-
petitive polymerase chain reaction in PBMC: lack of corre-
spondence with common allelic variants. J Bone Miner Res 12:
726–733.
28. Schlesinger LS, Horwitz MA, 1990. Phagocytosis of leprosy ba-
cilli is mediated by complement receptors CR1 and CR3 on
human monocytes and complement component C3 in serum. J
Clin Invest 85: 1304–1314.
29. Hirsch CS, Ellner JJ, Russell DG, Rich EA, 1994. Complement
receptor-mediated uptake and tumor necrosis factor-alpha-
mediated growth inhibition of Mycobacterium tuberculosis by
human alveolar macrophages. J Immunol 152: 743–753.
30. Moulds JM, Zimmerman PA, Doumbo OK, Kassambara L, Sa-
gara I, Diallo DA, Atkinson JP, Krych-Goldberg M, Hauhart
RE, Hourcade DE, McNamara DT, Birmingham DJ, Rowe
JA, Moulds JJ, Miller LH, 2001. Molecular identification of
Knops blood group polymorphisms found in long homologous
region D of complement receptor 1. Blood 97: 2879–2885.
31. Xiang L, Rundles JR, Hamilton DR, Wilson JG, 1999. Quanti-
tative alleles of CR1: coding sequence analysis and comparison
of haplotypes in two ethnic groups. J Immunol 163: 4939–4945.
32. Zimmerman PA, Fitness J, Moulds JM, McNamara DT, Kase-
hagen LJ, Rowe JA, Hill AV, 2003. CR1 Knops blood group
alleles are not associated with severe malaria in the Gambia.
Genes Immun 4: 368–373.
33. Knight JC, Udalova I, Hill AV, Greenwood BM, Peshu N, Marsh
K, Kwiatkowski D, 1999. A polymorphism that affects OCT-1
binding to the TNF promoter region is associated with severe
malaria. Nat Genet 22: 145–150.
34. Cabrera M, Shaw MA, Sharples C, Williams H, Castes M, Convit
J, Blackwell JM, 1995. Polymorphism in tumor necrosis factor
genes associated with mucocutaneous leishmaniasis. J Exp
Med 182: 1259–1264.
35. Sashio H, Tamura K, Ito R, Yamamoto Y, Bamba H, Kosaka T,
Fukui S, Sawada K, Fukuda Y, Satomi M, Shimoyama T, Fu-
ruyama J, 2002. Polymorphisms of the TNF gene and the TNF
receptor superfamily member 1B gene are associated with sus-
ceptibility to ulcerative colitis and Crohn’s disease, respec-
tively. Immunogenetics 53: 1020–1027.
36. Santos AR, Almeida AS, Suffys PN, Moraes MO, Filho VF, Mat-
tos HJ, Nery JA, Cabello PH, Sampaio EP, Sarno EN, 2000.
Tumor necrosis factor promoter polymorphism (TNF2) seems
to protect against development of severe forms of leprosy in a
pilot study in Brazilian patients. Int J Lepr Other Mycobact Dis
68: 325–327.
37. Moraes MO, Duppre NC, Suffys PN, Santos AR, Almeida AS,
Nery JA, Sampaio EP, Sarno EN, 2001. Tumor necrosis factor-
alpha promoter polymorphism TNF2 is associated with a
stronger delayed-type hypersensitivity reaction in the skin of
borderline tuberculoid leprosy patients. Immunogenetics 53:
45–47.
38. Roy S, McGuire W, Mascie-Taylor CG, Saha B, Hazra SK, Hill
AV, Kwiatkowski D, 1997. Tumor necrosis factor promoter
polymorphism and susceptibility to lepromatous leprosy. J In-
fect Dis 176: 530–532.
39. Bayley JP, de Rooij H, van den Elsen PJ, Huizinga TW, Verweij
CL, 2001. Functional analysis of linker-scan mutants spanning
the -376, -308, -244, and -238 polymorphic sites of the TNF-
alpha promoter. Cytokine 14: 316–323.
40. Udalova IA, Richardson A, Denys A, Smith C, Ackerman H,
Foxwell B, Kwiatkowski D, 2000. Functional consequences of
a polymorphism affecting NF-kappaB p50-p50 binding to the
TNF promoter region. Mol Cell Biol 20: 9113–9119.
41. Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW,
Kimberly RP, 2001. Novel single nucleotide polymorphisms in
the distal IL-10 promoter affect IL-10 production and enhance
the risk of systemic lupus erythematosus. J Immunol 166:
3915–3922.
42. Rees LE, Wood NA, Gillespie KM, Lai KN, Gaston K, Mathie-
son PW, 2002. The interleukin-10-1082 G/A polymorphism:
allele frequency in different populations and functional signifi-
cance. Cell Mol Life Sci 59: 560–569.
43. Krutzik SR, Ochoa MT, Sieling PA, Uematsu S, Ng YW, Legaspi
A, Liu PT, Cole ST, Godowski PJ, Maeda Y, Sarno EN, Nor-
gard MV, Brennan PJ, Akira S, Rea TH, Modlin RL, 2003.
Activation and regulation of Toll-like receptors 2 and 1 in
human leprosy. Nat Med 9: 525–532.
44. Means TK, Wang S, Lien E, Yoshimura A, Golenbock DT, Fen-
ton MJ, 1999. Human toll-like receptors mediate cellular acti-
vation by Mycobacterium tuberculosis. J Immunol 163: 3920–
3927.
45. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M,
Frees K, Watt JL, Schwartz DA, 2000. TLR4 mutations are
associated with endotoxin hyporesponsiveness in humans. Nat
Genet 25: 187–191.
46. Lorenz E, Mira JP, Frees KL, Schwartz DA, 2002. Relevance of
mutations in the TLR4 receptor in patients with gram-negative
septic shock. Arch Intern Med 162: 1028–1032.
47. Garred P, Madsen HO, Kurtzhals JA, Lamm LU, Thiel S, Hey
AS, Svejgaard A, 1992. Diallelic polymorphism may explain
variations of the blood concentration of mannan-binding pro-
tein in Eskimos, but not in black Africans. Eur J Immunogenet
19: 403–412.
48. Garred P, Harboe M, Oettinger T, Koch C, Svejgaard A, 1994.
Dual role of mannan-binding protein in infections: another
case of heterosis? Eur J Immunogenet 21: 125–131.
49. Lio D, Marino V, Serauto A, Gioia V, Scola L, Crivello A, Forte
GI, Colonna-Romano G, Candore G, Caruso C, 2002. Geno-
type frequencies of the +874T→A single nucleotide polymor-
phism in the first intron of the interferon-gamma gene in a
sample of Sicilian patients affected by tuberculosis. Eur J Im-
munogenet 29: 371–374.
50. Rossouw M, Nel HJ, Cooke GS, van Helden PD, Hoal EG,
2003. Association between tuberculosis and a polymorphic
NFkappaB binding site in the interferon gamma gene. Lancet
361: 1871–1872.
51. Abel L, Sanchez FO, Oberti J, Thuc NV, Hoa LV, Lap VD,
Skamene E, Lagrange PH, Schurr E, 1998. Susceptibility to
leprosy is linked to the human NRAMP1 gene. J Infect Dis
177: 133–145.
52. Shaw MA, Atkinson S, Dockrell H, Hussain R, Lins-Lainson Z,
Shaw J, Ramos F, Silveira F, Mehdi SQ, Kaukab F, 1993. An
RFLP map for 2q33-q37 from multicase mycobacterial and
leishmanial disease families: no evidence for an Lsh/Ity/Bcg
gene homologue influencing susceptibility to leprosy. Ann
Hum Genet 57: 251–271.
53. Meisner SJ, Mucklow S, Warner G, Sow SO, Lienhardt C, Hill
AV, 2001. Association of NRAMP1 polymorphism with lep-
rosy type but not susceptibility to leprosy per se in west Afri-
cans. Am J Trop Med Hyg 65: 733–735.
54. Medina E, Rogerson BJ, North RJ, 1996. The Nramp1 antimi-
crobial resistance gene segregates independently of resistance
to virulent Mycobacterium tuberculosis. Immunology 88: 479–
481.
55. Alcais A, Sanchez FO, Thuc NV, Lap VD, Oberti J, Lagrange
PH, Schurr E, Abel L, 2000. Granulomatous reaction to intra-
dermal injection of lepromin (Mitsuda reaction) is linked to
the human NRAMP1 gene in Vietnamese leprosy sibships. J
Infect Dis 181: 302–308.
56. Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC,
Hill AV, 1998. Variations in the NRAMP1 gene and suscep-
tibility to tuberculosis in west Africans. N Engl J Med 338:
640–644.
57. Wallace C, Clayton D, Fine P, 2003. Estimating the relative re-
currence risk ratio for leprosy in Karonga District, Malawi.
Lepr Rev 74: 133–140.
FITNESS AND OTHERS340
